ランキング価格はじめての方へ
  1. 米国企業
  2. Moderna, Inc.
  3. Raw

Moderna, Inc.MRNA

時価総額
$126.7億
PER
mRNA医薬品の大手。mRNAワクチンや治療候補を展開。メルクとの提携や2016年の協業開始、2022年10月のオプション行使で2.5億ドル受領。2024年の製品売上は31億ドル、現金等は95億ドル保有。米国・欧州・アジアで展開。
概要財務
サマリーテーブルに戻る
2018年
12月31日		2019年
12月31日		2020年
12月31日		2021年
12月31日		2022年
12月31日		2023年
12月31日		2024年
12月31日
Net (loss) income-385-514-74712,2028,362-4,714-3,561
Stock-based compensation738193142226305429
Depreciation and amortization-----621189
Amortization/accretion of investments24-10-54-316195
Loss on equity investments, net------35-52
Other non-cash items-----28-7-60
Accounts receivable, net-0-71,3851,784-1,790-493-534
Prepaid expenses and other assets5-102414891,699-974-145
Inventory--471,394-492-747-83
Right-of-use assets, operating leases------53
Accounts payable15-241220424013-69
Accrued liabilities9-3388989612-340-385
Deferred revenue--3,8422,824-4,157-2,060-439
Operating lease liabilities---17-1455128
Other liabilities1-66123887378
Net cash (used in) provided by operating activities-331-4592,02713,6204,981-3,118-3,004
Purchases of marketable securities1,2281,1452,95612,65211,4353,7606,529
Proceeds from maturities of marketable securities7839931,1371,3383,1515,5755,562
Proceeds from sales of marketable securities1771692153,1053,5483,2063,967
Purchases of property, plant and equipment10632672844007071,051
Acquisition of business, net of cash acquired-----85-
Investment in convertible notes and equity securities---304023-
Net cash provided by (used in) investing activities-372-15-1,672-8,523-5,1764,2061,949
Proceeds from Stock Plans147180124654666
Repurchase of common stock, including excise tax---8573,3291,153-
Changes in financing lease liabilities----18427010
Net cash provided by (used in) financing activities1,227512,033-873-3,448-1,37756
Net decrease in cash, cash equivalents and restricted cash--4232,3884,224-3,643-289-999
Income Taxes Paid, Net0014802,729-357197
Cash paid for interest3-914253924
Capital Expenditures Incurred but Not yet Paid135181117213097